PRS15 A Cost-Utility Analysis of Dacomitinib As First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 21 L858R Substitution Mutation in China
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.1079
https://www.valueinhealthjournal.com/article/S1098-3015(21)01296-1/fulltext
Title :
PRS15 A Cost-Utility Analysis of Dacomitinib As First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 21 L858R Substitution Mutation in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01296-1&doi=10.1016/j.jval.2021.04.1079
First page :
Section Title :
Open access? :
No
Section Order :
10573